4.6 Review

Evaluating the potential of IL-27 as a novel therapeutic agent in HIV-1 infection

Journal

CYTOKINE & GROWTH FACTOR REVIEWS
Volume 24, Issue 6, Pages 571-577

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.cytogfr.2013.07.001

Keywords

Interleukin-27; HIV; Cytokines; SPTBN1; Therapy

Funding

  1. National Cancer Institute, National Institutes of Health [HHSN261200800001E]
  2. National Institute of Allergy and Infectious Disease

Ask authors/readers for more resources

Interleukin 27 (IL-27) is an immunomodulatory cytokine with important roles in both the innate and adaptive immune systems. In the last five years, the addition of exogenous IL-27 to primary cell cultures has been demonstrated to decrease HIV-1 replication in a number of cell types including peripheral blood mononuclear cells (PBMCs), CD4+ T cells, macrophages and dendritic cells. These in vitro findings suggest that IL-27 may have therapeutic value in the setting of HIV-1 infection. In this review, we describe the current knowledge of the biology of IL-27, its effects primarily on HIV-1 replication but also in other viral infections and explore its potential role as a therapeutic cytokine for the treatment of patients with HIV-1 infection. (C) 2013 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available